Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F, Recchia AG, Vigna E, De Stefano L, Bossio S, Morabito L, Pellicanò M, Palummo A, Storino F, Caruso N, Gentile M. Morabito F, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2015 Jun;24(6):795-807. doi: 10.1517/13543784.2015.1021920. Epub 2015 Mar 1. Expert Opin Investig Drugs. 2015. PMID: 25728009 Review.
Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F. Gentile M, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. Expert Opin Investig Drugs. 2017. PMID: 28972395 Review.
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Petrungaro A, Gentile M, Mazzone C, Greco R, Uccello G, Recchia AG, De Stefano L, Bossio S, Palummo A, Morelli R, Musolino C, Morabito F, Vigna E. Petrungaro A, et al. Among authors: bossio s. Chemotherapy. 2017;62(6):353-356. doi: 10.1159/000477714. Epub 2017 Aug 16. Chemotherapy. 2017. PMID: 28810255 Free article.
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence.
Cutrona G, Tripodo C, Matis S, Recchia AG, Massucco C, Fabbi M, Colombo M, Emionite L, Sangaletti S, Gulino A, Reverberi D, Massara R, Boccardo S, de Totero D, Salvi S, Cilli M, Pellicanò M, Manzoni M, Fabris S, Airoldi I, Valdora F, Ferrini S, Gentile M, Vigna E, Bossio S, De Stefano L, Palummo A, Iaquinta G, Cardillo M, Zupo S, Cerruti G, Ibatici A, Neri A, Fais F, Ferrarini M, Morabito F. Cutrona G, et al. Among authors: bossio s. Sci Transl Med. 2018 Feb 14;10(428):eaal1571. doi: 10.1126/scitranslmed.aal1571. Sci Transl Med. 2018. PMID: 29444977
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.
Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG, De Stefano L, Campanelli M, Giannarelli D, Bossio S, Morabito L, Vigna E, Gaidano G, Foà R, Morabito F. Gentile M, et al. Among authors: bossio s. Br J Haematol. 2014 Oct;167(2):224-32. doi: 10.1111/bjh.13032. Epub 2014 Jul 11. Br J Haematol. 2014. PMID: 25041609 Free article.
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
Morabito F, Tripepi G, Vigna E, Bossio S, D'Arrigo G, Martino EA, Storino F, Recchia AG, Fronza G, Di Raimondo F, Colombo M, Fais F, Neri A, Cutrona G, Ferrarini M, Gentile M. Morabito F, et al. Among authors: bossio s. Eur J Haematol. 2021 Jun;106(6):831-835. doi: 10.1111/ejh.13614. Epub 2021 Apr 7. Eur J Haematol. 2021. PMID: 33662164 Free article. Clinical Trial.
An old drug with a new future: bendamustine in multiple myeloma.
Gentile M, Recchia AG, Mazzone C, Vigna E, Martino M, Morabito L, Lucia E, Bossio S, De Stefano L, Granata T, Palummo A, Morabito F. Gentile M, et al. Among authors: bossio s. Expert Opin Pharmacother. 2013 Nov;14(16):2263-80. doi: 10.1517/14656566.2013.837885. Epub 2013 Sep 21. Expert Opin Pharmacother. 2013. PMID: 24053161 Review.
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR, Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R, Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini M, Trentin L, Gattei V, Morabito F. Gentile M, et al. Among authors: bossio s. Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3. Blood Cancer J. 2020. PMID: 32938904 Free PMC article. No abstract available.
47 results